JP2025000628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025000628A5 JP2025000628A5 JP2024151952A JP2024151952A JP2025000628A5 JP 2025000628 A5 JP2025000628 A5 JP 2025000628A5 JP 2024151952 A JP2024151952 A JP 2024151952A JP 2024151952 A JP2024151952 A JP 2024151952A JP 2025000628 A5 JP2025000628 A5 JP 2025000628A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- protein
- domain
- nkp46
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 62
- 229920001184 polypeptide Polymers 0.000 claims 60
- 102000004196 processed proteins & peptides Human genes 0.000 claims 60
- 108090000623 proteins and genes Proteins 0.000 claims 44
- 102000004169 proteins and genes Human genes 0.000 claims 44
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 claims 6
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 6
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 6
- 102000050738 human NCR1 Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000053350 human FCGR3B Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101150019418 IGHV4-30-4 gene Proteins 0.000 claims 1
- 101150050798 IGKV1-39 gene Proteins 0.000 claims 1
- 101000589304 Macaca fascicularis Natural cytotoxicity triggering receptor 1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000025171 antigen binding proteins Human genes 0.000 claims 1
- 108091000831 antigen binding proteins Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271474P | 2015-12-28 | 2015-12-28 | |
| US62/271,474 | 2015-12-28 | ||
| PCT/EP2016/081953 WO2017114694A1 (en) | 2015-12-28 | 2016-12-20 | VARIABLE REGIONS FOR NKp46 BINDING PROTEINS |
| JP2018552124A JP7091250B2 (ja) | 2015-12-28 | 2016-12-20 | NKp46結合タンパク質の可変領域 |
| JP2022096649A JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | NKp46結合タンパク質の可変領域 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096649A Division JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | NKp46結合タンパク質の可変領域 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025000628A JP2025000628A (ja) | 2025-01-07 |
| JP2025000628A5 true JP2025000628A5 (cg-RX-API-DMAC7.html) | 2025-04-14 |
Family
ID=57796296
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552124A Active JP7091250B2 (ja) | 2015-12-28 | 2016-12-20 | NKp46結合タンパク質の可変領域 |
| JP2022096649A Active JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | NKp46結合タンパク質の可変領域 |
| JP2024151952A Pending JP2025000628A (ja) | 2015-12-28 | 2024-09-04 | NKp46結合タンパク質の可変領域 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552124A Active JP7091250B2 (ja) | 2015-12-28 | 2016-12-20 | NKp46結合タンパク質の可変領域 |
| JP2022096649A Active JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | NKp46結合タンパク質の可変領域 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11001629B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3397645B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7091250B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN108779175B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016383475B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3007898A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017114694A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6822849B2 (ja) * | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的NKp46結合タンパク質 |
| US9767555B2 (en) * | 2015-01-05 | 2017-09-19 | Case Western Reserve University | Disease characterization from fused pathology and radiology data |
| AU2016284871B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| EP3325967B1 (en) | 2015-07-24 | 2019-12-04 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
| CA3007898A1 (en) | 2015-12-28 | 2017-07-06 | Innate Pharma | Variable regions for nkp46 binding proteins |
| FR3061716B1 (fr) * | 2017-01-06 | 2019-05-17 | Elsalys Biotech | Nouveaux composes ciblant le cd160 humain |
| AU2018213823B2 (en) | 2017-01-24 | 2024-11-07 | Innate Pharma | NKp46 binding agents |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| EP3713959A1 (en) | 2017-11-21 | 2020-09-30 | Innate Pharma | Multispecific antigen binding proteins |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| CN112384534A (zh) | 2018-05-21 | 2021-02-19 | 指南针制药有限责任公司 | 用于增强nk细胞对靶细胞的杀死的组合物和方法 |
| CN110540590B (zh) | 2018-05-29 | 2023-08-18 | 康诺亚生物医药科技(成都)有限公司 | 一种自免疫抑制物的开发和应用 |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| JP2022525703A (ja) * | 2019-03-20 | 2022-05-18 | ジャベリン・オンコロジー・インコーポレイテッド | 抗adam12抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法 |
| US11896619B2 (en) | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
| KR20220164787A (ko) | 2020-04-06 | 2022-12-13 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 암 및 감염의 치료를 위한 NKp46에 대한 항체 및 이의 작제물 |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| CN113637074B (zh) * | 2020-05-11 | 2024-09-24 | 上海怀越生物科技有限公司 | NKp46抗体及其制备方法和应用 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| AU2021301788A1 (en) * | 2020-06-30 | 2023-01-19 | Gaia Biomedicine Inc. | Method for stabilizing binding of NK cell and antibody, and use thereof |
| CN116063550A (zh) * | 2020-09-02 | 2023-05-05 | 南京北恒生物科技有限公司 | 靶向nk激活性受体的嵌合抗原受体 |
| KR20250152662A (ko) * | 2020-12-31 | 2025-10-23 | 사노피 | NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자 |
| CN117255807A (zh) * | 2020-12-31 | 2023-12-19 | 赛诺菲 | 与NKp46和CD123结合的多功能自然杀伤(NK)细胞接合器 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| EP4303234A4 (en) * | 2021-03-05 | 2024-10-09 | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. | Antibody against nkp46 and application of antibody |
| CN117321087A (zh) * | 2021-03-26 | 2023-12-29 | 先天制药公司 | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 |
| KR20240019786A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체 |
| CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
| CN119039440A (zh) * | 2021-07-02 | 2024-11-29 | 来凯医药科技(上海)有限公司 | 活化的肝星状细胞(hsc)的消耗及其用途 |
| CN115611984B (zh) * | 2021-07-16 | 2026-06-23 | 上海怀越生物科技有限公司 | NKp46抗体及其制备方法和应用 |
| EP4423140A4 (en) * | 2021-10-27 | 2025-10-01 | Samyang Biopharm Usa Inc | ANTI-MIC ANTIBODIES WITH VARIANT FC DOMAINS |
| WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
| US20250143272A1 (en) * | 2022-01-25 | 2025-05-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric nkp46 |
| WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| CN116003595B (zh) * | 2022-07-11 | 2024-02-02 | 南方医科大学第三附属医院(广东省骨科研究院) | 靶向nk细胞nkp46受体的纳米抗体及其制备方法和应用 |
| CN119768434A (zh) * | 2022-08-19 | 2025-04-04 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗体及其应用 |
| CN116003627B (zh) * | 2022-09-16 | 2025-05-13 | 四川大学华西医院 | NKG2D-NKp46细胞接合器分子及其用途 |
| CN116284396B (zh) * | 2022-12-20 | 2025-03-28 | 合肥天港免疫药物有限公司 | NKp46抗体及其用途 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| WO2024224313A1 (en) | 2023-04-24 | 2024-10-31 | Sanofi | Use of cd123 nk cell engager for treating aml and related disorders |
| WO2024254772A1 (zh) * | 2023-06-14 | 2024-12-19 | 香港北恒生物科技有限公司 | 工程化的滋养细胞及其用途 |
| US20250064935A1 (en) | 2023-07-13 | 2025-02-27 | Sanofi | Natural killer cells and cd123 nk cell engager combination therapy |
| WO2025114919A1 (en) | 2023-11-28 | 2025-06-05 | Sanofi | Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders |
| CN117442721B (zh) * | 2023-12-20 | 2024-03-15 | 苏州艾凯利元生物科技有限公司 | 一种包括nk细胞和nk细胞接合器分子的组合物 |
| WO2026055280A1 (en) | 2024-09-04 | 2026-03-12 | Sanofi | Interleukin 2 (il-2) and cd123 nk cell engager combination therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2288307C (en) * | 1999-11-15 | 2012-05-15 | Universita Di Genova | Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |
| AU2003294930B2 (en) * | 2002-12-23 | 2008-12-04 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same |
| US7825085B2 (en) * | 2003-06-30 | 2010-11-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells |
| WO2005105848A1 (en) * | 2004-04-30 | 2005-11-10 | Innate Pharma | Compositions and methods for enhancing nk cell activity |
| EP1934260B1 (en) * | 2005-10-14 | 2017-05-17 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| WO2009026660A1 (en) * | 2007-08-30 | 2009-03-05 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| WO2012175613A1 (en) * | 2011-06-21 | 2012-12-27 | Innate Pharma | NKp46-MEDIATED NK CELL TUNING |
| WO2014125041A1 (en) * | 2013-02-14 | 2014-08-21 | Innate Pharma | Treatment of peripheral t cell lymphoma |
| WO2015015489A1 (en) * | 2013-07-30 | 2015-02-05 | Biolinerx Ltd. | Antibody for treating diabetes and autoimmune diseases |
| WO2015138600A2 (en) | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| JP6822849B2 (ja) * | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的NKp46結合タンパク質 |
| AU2016284871B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| CA3007898A1 (en) | 2015-12-28 | 2017-07-06 | Innate Pharma | Variable regions for nkp46 binding proteins |
| AU2018213823B2 (en) | 2017-01-24 | 2024-11-07 | Innate Pharma | NKp46 binding agents |
-
2016
- 2016-12-20 CA CA3007898A patent/CA3007898A1/en active Pending
- 2016-12-20 WO PCT/EP2016/081953 patent/WO2017114694A1/en not_active Ceased
- 2016-12-20 JP JP2018552124A patent/JP7091250B2/ja active Active
- 2016-12-20 US US16/066,688 patent/US11001629B2/en active Active
- 2016-12-20 CN CN201680082632.4A patent/CN108779175B/zh active Active
- 2016-12-20 EP EP16826025.5A patent/EP3397645B1/en active Active
- 2016-12-20 AU AU2016383475A patent/AU2016383475B2/en active Active
- 2016-12-20 CN CN202210862118.XA patent/CN115925933A/zh active Pending
-
2021
- 2021-05-10 US US17/315,547 patent/US11891444B2/en active Active
-
2022
- 2022-06-15 JP JP2022096649A patent/JP7551693B2/ja active Active
-
2024
- 2024-02-05 US US18/432,126 patent/US20240174748A1/en not_active Abandoned
- 2024-09-04 JP JP2024151952A patent/JP2025000628A/ja active Pending